Dendreon Finds a Buyer

Over the past month, shares of Dendreon (NASDAQ: DNDN  ) have risen 25%, amid talk that a buyout was a possibility. For now, that talk remains just talk; but the company has found a buyer for its New Jersey facility -- Novartis (NYSE: NVS  )  -- which will raise $43M for the company. In this video, Motley Fool health-care analyst David Williamson tells us why the sale was important for Dendreon, how Novartis will be putting its new facility to use, and if the rumor mill's buyout ideas may materialize somewhere down the road.

Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company, and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.


Read/Post Comments (4) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 21, 2012, at 2:08 PM, lebronz wrote:

    Looking good David. Good video!

    Yeah, don't expect any buyout soon because this company is not properly valuated as hedgefund/Bank institutions have driven down the price via shorting millions since Oct 2011...

    Nearly 24 million additional shorted since then for a current total of 44 million (peaked to 47 million a couple months ago).

    Accumulation of the shares via FEAR (competitive fears, non-sequencing drug fears, restructuring fears, etc...) is still occuring by those wanting in dndn before CEO JJ begins surprising late next year and into 2014.

    DNDN is on the precipice of busting through treating 1076 patients per quarter ($100M in rev) or 4304 patients annually.

    U.S. stats by American Cancer Societ:

    * 1-2 million men have pc.

    * 241,741 are newly diagnosed each year with pc

    * 30,000 are "newly diagnosed" throughout a year with mCRPC (Provenge label)

    * 60,000 are living with mCRPC (these terminal men typically have 2 years to live).

    *Baby boomer influx only increases the numbers.

    *Provenge protected with12 years market exclusivity from any biosimilar.

    Given above stats, dndn's breakeven or treating 4304 patients yearly is still barely making a dent in the 30k men newly diagnosed with mCRPC during a year.

    No, don't expect any takeover or you'll witness one helluva bidding war between large pharmas.

    The thought of a buyout makes for an interesting video report though ;)

    Happy Holidays Dave (& Bren)

    Leb

    ps: Keep telling EVERYONE about the dendreon story because greedy wallstreet is trying to collect all 154 million outstanding shares since raider Carl Icahn's former CEO choice for Imclone (J. Johnson) was elected back in Feb to lead DNDN.

  • Report this Comment On December 21, 2012, at 2:11 PM, lebronz wrote:

    Oh, and my dndn stock price target (by Dec, 2013) is a measly $10 bucks!

    But $1 million bucks becomes $2 million bucks

    ;o)

    gltu both

    Leb

  • Report this Comment On December 27, 2012, at 7:42 AM, lebronz wrote:

    Bren & Dave,

    Take a look: http://www.nasdaq.com/symbol/dndn/short-interest

    Some healthy wealthy entity(s) shorted 2.3 million during 11/30 - 12/14.

    During those 10 trading days the stock price actually moved from $4.40 - $5 so buying was occurring, but the millions being shorted thwarted real upward movement.

    After seeing hard short data like this, you have to believe something is going on :-D

    If you don't believe some "price managing" isn't going on...lol...U don't know how greedy wall street works and how they leverage time & fear to drive/keep away investors from their diamond picks.

    Remember, dndn is in the early stages of commercial growth.

    April 2010 was FDA approval of Provenge.

    Year 1, 2, & 3 (2010-2012) was dealing w/ the CMS issue, mfg ramping, and some restructuring...

    And I won't mention the fantastic YOY provenge revenue sales growth.

    Year 4, 5, & 6 (2013-2015) will b growth years and coincidentally will follow the vesting of 1000's of new stock/options issued to all new hires, new officers, and soon CEO JJ to issue himself this /jan-Feb.

    The debt (notes) become due in Jan, 2016

    And we're still only in year 7 out of the 12 years of market exclusivity that dndn provenge will enjoy under Obamacare :-]

    Tell all you know about dndn. Help the 99% & don't let greedy wall street (that gets away w/ ponzi schemes, high freq trading, insider trading, naked short selling, massive short selling, Libor rigging, & the occassional flash crash, etc, etc) have dndn's 154 million shares all to themselves!

    Happy New Yearz!

    Leb

    Ps; Institutional holdings haven't wavered one iota (still at 60% ;•)

  • Report this Comment On December 27, 2012, at 7:52 AM, lebronz wrote:

    ps; Meant to say, institute holdings haven't wavered one iota this year...during all the purported fear of restructuring, layoffs, competitive fears (zytiga, mdv, etc), and non-sequencing fears...lol

Add your comment.

DocumentId: 2164946, ~/Articles/ArticleHandler.aspx, 4/19/2014 10:40:17 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement